{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["121(8)"],"submitter":["Xu Y"],"pubmed_abstract":["<h4>Background</h4>Small-cell lung cancer (SCLC) remains an aggressive cancer with short-term survival due to limited therapeutic options. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2. This study aimed to investigate the efficacy and safety of apatinib in patients with extensive-stage (EC) SCLC who had progressed after two or three previous therapies.<h4>Methods</h4>Eligible patients were histologically confirmed ES-SCLC after two or three previous treatments, including a platinum-based regimen. Patients received apatinib at an initial dose of 500 mg once daily. The primary endpoint was the objective response rate.<h4>Results</h4>Forty patients were enrolled. At the data cut-off time (November 15, 2018), the "],"journal":["British journal of cancer"],"pagination":["640-646"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6889407"],"repository":["biostudies-literature"],"pubmed_title":["Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study."],"pmcid":["PMC6889407"],"pubmed_authors":["Chen K","Fan Y","Chen J","Chen M","Qin J","Han N","Jin Y","Shi X","Zhang P","Li W","Li Y","Xie F","Huang Z","Lu H","Gong L","Xu X","Zhao J","Xu W","Yu X","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.","description":"<h4>Background</h4>Small-cell lung cancer (SCLC) remains an aggressive cancer with short-term survival due to limited therapeutic options. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2. This study aimed to investigate the efficacy and safety of apatinib in patients with extensive-stage (EC) SCLC who had progressed after two or three previous therapies.<h4>Methods</h4>Eligible patients were histologically confirmed ES-SCLC after two or three previous treatments, including a platinum-based regimen. Patients received apatinib at an initial dose of 500 mg once daily. The primary endpoint was the objective response rate.<h4>Results</h4>Forty patients were enrolled. At the data cut-off time (November 15, 2018), the ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Oct","modification":"2026-04-29T17:19:35.809Z","creation":"2020-09-18T07:07:40Z"},"accession":"S-EPMC6889407","cross_references":{"pubmed":["31523058"],"doi":["10.1038/s41416-019-0583-6"]}}